Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer
Status:
Terminated
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth and by blocking blood flow to the tumor. Giving sorafenib before and after surgery may
be an effective treatment for kidney cancer. This phase II trial is studying how well
sorafenib works in treating patients who are undergoing surgery for metastatic kidney cancer.